
FDA Creates New Safety Body for Biologics
The US Food and Drug Administration launched a new internal safety body to provide independent oversight of approved vaccines, gene therapies and blood products. The CBER Safety Council aims to enhance accountability and monitor emerging risks across broader patient populations.

The United States Food and Drug Administration established an internal safety body to oversee approved biologics, separating post-market reviews from product approval offices. The new CBER Safety Council formalizes independent oversight for vaccines, gene therapies, and blood products. This structural overhaul aims to strengthen post-market surveillance as advanced medical treatments reach broader patient populations.











